Abstract:The aim of this study was to investigate the plasma proteome in individuals with intracranial aneurysms (IAs) and identify biomarkers associated with the formation and rupture of IAs. Proteomic profiles ( N = 1069 proteins) were assayed in plasma ( N = 120) collected from patients with ruptured and unruptured intracranial aneurysms (RIA and UIA), traumatic subarachnoid hemorrhage (tSAH), and healthy controls (HC) using tandem mass tag (TMT) labeling quantitative proteomics analysis. Gene ontology (GO) and pathway analysis revealed that these relevant proteins were involved in immune response and extracellular matrix organization pathways. Seven candidate biomarkers were verified by ELISA in a completely separate cohort for validation ( N = 90). Among them, FN1, PON1, and SERPINA1 can be utilized as diagnosis biomarkers of IA, with a combined area under the ROC curve of 0.891. The sensitivity was 93.33%, specificity was 75.86%, and accuracy was 87.64%. PFN1, ApoA-1, and SERPINA1 can serve as independent risk factors for predicting aneurysm rupture. The combined prediction of aneurysm rupture yielded an area under the ROC curve of 0.954 with a sensitivity of 96.15%, specificity of 81.48%, and accuracy of 88.68%. This prediction model was more effective than PHASES score. In conclusion, high-throughput proteomics analysis with population validation was performed to assess blood-based protein expression characteristics. This revealed the potential mechanism of IA formation and rupture, facilitating the discovery of biomarkers. Significance Although the annual rupture rate of small unruptured aneurysms is believed to be minimal, studies have indicated that ruptured aneurysms typically have an average size of 6.28 mm, with 71.8% of them being <7 mm in diameter. Hence, evaluating the possibility of rupture in UIA and making a choice between aggressive treatment and conservative observation emerges as a significant challenge in the management of UIA. No biomarker or scoring system has been able to satisfactorily address this issue to date. It would be significant to develop biomarkers that could be used for early diagnosis of IA as well as for prediction of IA rupture. After TMT proteomics analysis and ELISA validation in independent populations, we found that FN1, PON1, and SERPINA1 can be utilized as diagnostic biomarkers for IA, and PFN1, ApoA-1, and SERPINA1 can serve as independent risk factors for predicting aneurysm rupture. Especially, when combined with ApoA-1, SERPINA1, and PFN1 for predicting IA rupture, the area under the curve (AUC) was 0.954 with a sensitivity of 96.15%, specificity of 81.48%, and accuracy of 88.68%. This prediction model was more effective than PHASES score.

Comprehensive plasma lipidomic profiles reveal a lipid-based signature panel as a diagnostic and predictive biomarker for cerebral aneurysms

Plasma Lipidomics Identifies Unique Lipid Signatures and Potential Biomarkers for Patients With Aortic Dissection

In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease

Alterations of NMR-Based Lipoprotein Profile Distinguish Unstable Angina Patients with Different Severity of Coronary Lesions

Novel Insights into Causal Effects of Serum Lipids, Lipid Metabolites, and Lipid-Modifying Targets on the Risk of Intracerebral Aneurysm.

Comprehensive Metabolomics Identified the Prominent Role of Glycerophospholipid Metabolism in Coronary Artery Disease Progression

Plasma metabolic signatures for intracranial aneurysm and its rupture identified by pseudotargeted metabolomics

Association of serum lipidomic profiles with risk of intracranial aneurysm: A Mendelian randomization study

Plasma Metabolic Signatures for Intracranial Aneurysm and Its Rupture Identified by Pseudotargeted Metabolomics.

Correlation of Lipoprotein-Associated Phospholipase A2 and Cerebral Microbleeds in Patients with Acute Ischaemic Stroke

Plasma lipidomic biomarker analysis reveals distinct lipid changes in vascular dementia.

Association Between Plasma Lipoprotein-Associated Phospholipase A2 and Plaque Vulnerability in TIA Patients With Unilateral Middle Cerebral Artery Stenosis

Plasma biomarkers distinguish Boston Criteria 2.0 cerebral amyloid angiopathy from healthy controls

Lipoprotein-associated phospholipase A2 activity levels is associated with artery to artery embolism in symptomatic intracranial atherosclerotic disease

Plasma proteomics analysis reveals potential biomarkers for intracranial aneurysm formation and rupture

Identification of Novel Plasma Biomarkers for Abdominal Aortic Aneurysm by Protein Array Analysis

Untargeted metabolomics to detect and identify plasma metabolic signatures associated with intracranial aneurysm and its rupture

Plasma lncRNA LIPCAR Expression Levels Associated with Neurological Impairment and Stroke Subtypes in Patients with Acute Cerebral Infarction: A Prospective Observational Study with a Control Group

Comprehensive Mass Spectrometry for Development of Proteomic Biomarkers of Intracranial Aneurysms.

Differential Lipid Signatures of Lumbar and Cisternal Cerebrospinal Fluid

Circulating Proteomic Panels for Risk Stratification of Intracranial Aneurysm and Its Rupture